ClinicalTrials.gg
RecruitingNCT06483737Updated Aug 26, 2025

Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE)

An interventional study of Human albumin infusion at a modified dosage and Human albumin infusion at a routine dosage in Overt Hepatic Encephalopathy, sponsored by General Hospital of Shenyang Military Region. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-26.

Sponsored by General Hospital of Shenyang Military Region · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
174
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Hepatic Encephalopathy with a site in China — 16 open to participants now, 18 under way, none of them phase 3. Hepatic Encephalopathy · China.

Planned enrollment
6th of 17
174 · median 100
Started
2025
with 3 others
No phase
11 of 26
7 open now
Primary completion
2027-06
later than 7 of 17 live
Registered
13th of 26
by date
Lead sponsor
1 of 26
General Hospital of Shenyang Military Region

Among the 26 studies in Hepatic Encephalopathy with a site in China, this one is the 6th largest by planned enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2025, is one of 11 with no phase, reaches primary completion later than 7 of the 17 other live ones, and was the 13th registered.

Hepatic Encephalopathy

225 studies on the registry are indexed under Hepatic Encephalopathy; 53 are open to participants now.

Browse Hepatic Encephalopathy studies →

Open to participants now

16 of the 26 studies in Hepatic Encephalopathy with a site in China are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 30 Hepatic Encephalopathy studies recruiting now, 12 (40%) set no upper age limit and 13 (43%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Hepatic Encephalopathy with a site in China, or all of them as a file.
02

Study summary

Hepatic encephalopathy (HE), a severe complication of decompensated cirrhosis, is characterized as neurocognitive dysfunction. Emerging evidence suggests the potential role of human albumin infusion for the treatment of HE, but its optimal dosage remains undefined. Therefore, the investigators planned a randomized controlled trial (RCT) to compare the efficacy of human albumin infusion at different dosages in in patients with liver cirrhosis and overt HE.

Read the detailed description

Overall, 174 patients with a diagnosis of liver cirrhosis, overt HE, and a serum albumin level of 23-30g/L will be enrolled. They will be stratified according to the severity of overt HE and randomly assigned at a ratio of 1:1 into the groups of human albumin infusion at a modified dosage and a routine dosage. The primary endpoint is the improvement of overt HE within 3-5 days after treatment. The secondary endpoints include recurrence of overt HE, survival, and adverse events.

03

Conditions studied

  • Overt Hepatic Encephalopathy

Keywords

  • hepatic encephalopathy
  • liver cirrhosis
  • human albumin
  • inflammation
  • oxidative stress
  • survival
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A definite diagnosis of liver cirrhosis and overt HE
  • A serum albumin level of 23-30g/L
  • Age ≥18 years old
  • Sign the

Exclusion criteria

Exclusion Criteria:

  • to human albumin infusion
  • A history of transjugular intrahepatic portosystemic shunt
  • A diagnosis of acute liver failure
  • Severe heart and/or lung diseases
  • Psychiatric or nervous diseases
  • Pregnant or lactating
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
174 participants (estimated)

Study arms

  • Experimental
    Modified dosage group

    Intravenous infusion of human albumin 30-60g.

    Drug: Human albumin infusion at a modified dosage · Drug: Lactulose · Drug: Rifaximin · Drug: Ornithine Aspartate · Drug: Branched-Chain Amino Acids · Drug: Arginine

  • Active comparator
    Routine dosage group

    Intravenous infusion of human albumin 10-20g.

    Drug: Human albumin infusion at a routine dosage · Drug: Lactulose · Drug: Rifaximin · Drug: Ornithine Aspartate · Drug: Branched-Chain Amino Acids · Drug: Arginine

Interventions

  • DrugHuman albumin infusion at a modified dosage

    Participants receive intravenous infusion of human albumin at different dosages according to the serum albumin level.

    Also known as: AlbuRx

  • DrugHuman albumin infusion at a routine dosage

    Participants receive intravenous infusion of human albumin according to the current clinical practice.

    Also known as: AlbuRx

  • All participants will receive standard treatment of overt HE according to the current practice guideline.

    Also known as: Duphalac

  • All participants will receive standard treatment of overt HE according to the current practice guideline.

    Also known as: Xifaxan

  • DrugOrnithylaspartateStudies of OrnithylaspartateOrnithylaspartate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    All participants will receive standard treatment of overt HE according to the current practice guideline.

  • DrugAmino Acids, Branched-ChainStudies of Amino Acids, Branched-ChainAmino Acids, Branched-Chain pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    All participants will receive standard treatment of overt HE according to the current practice guideline.

    Also known as: Compound amino acid injection

  • All participants will receive standard treatment of overt HE according to the current practice guideline.

    Also known as: Arginine Hydrochloride Injection

06

What researchers measure

Primary outcomes

  1. Change of overt HE.

    The change of HE is defined as a decrease or an increase of at least one grade of the West Haven criteria after treatment.

    Time frame: 3-5 days

Secondary outcomes

  1. Reversal of overt HE.

    The reversal of HE is defined as clinical symptoms of overt HE disappear after treatment.

    Time frame: 3-5 days

  2. Recurrence of overt HE.

    Clinical symptoms related to overt HE recur and can be diagnosed with overt HE again according to the West Haven criteria.

    Time frame: 3 months

  3. Adverse events

    Adverse events will be monitored, including allergy, heart failure, pulmonary edema, acute hemolysis, renal dysfunction, and neuropsychiatric abnormalities.

    Time frame: 3 months

  4. Survival

    All participants will be followed by telephone to record survival status, including the major cause and date of death.

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Bai Z, Mendez-Sanchez N, Romeiro FG, Mancuso A, Philips CA, Tacke F, Basaranoglu M, Primignani M, Ibrahim M, Wong YJ, Nery FG, Teschke R, Ferreira CN, Munoz AE, Pinyopornpanish K, Thevenot T, Singh SP, Mohanty A, Satapathy SK, Ridola L, Maruyama H, Cholongitas E, Levi Sandri GB, Yang L, Shalimar, Yang Y, Villa E, Krag A, Wong F, Jalan R, O'Brien A, Bernardi M, Qi X; Liver Cirrhosis-related Complications (LCC)-International Special Interest Group. Use of albumin infusion for cirrhosis-related complications: An international position statement. JHEP Rep. 2023 May 5;5(8):100785. doi: 10.1016/j.jhepr.2023.100785. eCollection 2023 Aug. PubMed 37456673 ↗
  • Sharma BC, Singh J, Srivastava S, Sangam A, Mantri AK, Trehanpati N, Sarin SK. Randomized controlled trial comparing lactulose plus albumin versus lactulose alone for treatment of hepatic encephalopathy. J Gastroenterol Hepatol. 2017 Jun;32(6):1234-1239. doi: 10.1111/jgh.13666. PubMed 27885712 ↗
  • Simon-Talero M, Garcia-Martinez R, Torrens M, Augustin S, Gomez S, Pereira G, Guevara M, Gines P, Soriano G, Roman E, Sanchez-Delgado J, Ferrer R, Nieto JC, Sunye P, Fuentes I, Esteban R, Cordoba J. Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study. J Hepatol. 2013 Dec;59(6):1184-92. doi: 10.1016/j.jhep.2013.07.020. Epub 2013 Jul 19. PubMed 23872605 ↗
  • China L, Freemantle N, Forrest E, Kallis Y, Ryder SD, Wright G, Portal AJ, Becares Salles N, Gilroy DW, O'Brien A; ATTIRE Trial Investigators. A Randomized Trial of Albumin Infusions in Hospitalized Patients with Cirrhosis. N Engl J Med. 2021 Mar 4;384(9):808-817. doi: 10.1056/NEJMoa2022166. PubMed 33657293 ↗
  • Bai Z, Bernardi M, Yoshida EM, Li H, Guo X, Mendez-Sanchez N, Li Y, Wang R, Deng J, Qi X. Albumin infusion may decrease the incidence and severity of overt hepatic encephalopathy in liver cirrhosis. Aging (Albany NY). 2019 Oct 8;11(19):8502-8525. doi: 10.18632/aging.102335. Epub 2019 Oct 8. PubMed 31596729 ↗
  • Li Q, Tong H, Liu X, Liao F, Ma H, Zhou Z, Liu F, Shi H, Wang Z, Sun Y, Yao Q, Feng Y, Li X, Feng J, He Z, Peng Y, Bai Z, Zhu R, Cheng D, Xu C, He S, Yu H, Xie C, Yuan J, Wang X, Yang H, Zou Y, Li S, Li T, Hu S, Chen C, Chen Z, Lantinga MA, Bernardi M, Qi X, Tang C; On the behalf of Young Member Group of Chinese Gastroenterology Society. Human Albumin infusion in liver Cirrhosis and overt Hepatic Encephalopathy (HACHE): protocol of an investigator-initiated, open-label, multicentre, randomised controlled trial. BMJ Open. 2025 Nov 5;15(11):e094300. doi: 10.1136/bmjopen-2024-094300. PubMed 41198206 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2027, 24 months after the start.

Of 26 interventional studies with no phase under Hepatic Encephalopathy, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 72. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2024
First posted
Jul 3, 2024
StartActual
Jun 24, 2025
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Aug 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06483737
Lead sponsor
General Hospital of Shenyang Military Region
Responsible party
Xingshun Qi (Director of Department of Gastroenterology, General Hospital of Shenyang Military Region) — Principal investigator
First posted
Jul 3, 2024
Start date
Jun 24, 2025
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Aug 26, 2025

Study contacts

Xingshun Qi
Contact
xingshunqi@126.com
18909881019
Qianqian Li
Contact
1208594776@qq.com
13940307473
Xingshun Qi
principal investigator · Department of Gastroenterology, General Hospital of Northern Theater Command

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion